Bial
Tracked across 1 events · 6 articles · First seen May 26, 2026 · Last active Jun 09, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Bial announced the completion of its Phase 2b ACTIVATE study for Pariceract, which subsequently failed to meet its primary and key secondary efficacy endpoints, leading to the discontinuation of the drug's development for GBA1-associated Parkinson s disease. This represents a significant setback for Bial's R&D efforts in neurosciences.
May 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Bial live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard